{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T04:04:17Z","timestamp":1745121857552,"version":"3.40.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The use of weight-based unfractionated heparin (UFH) infusions is the standard of care in hospital management of venous thromboembolism (VTE). Initial dosing strategies for UFH in older adults and higher body weight patients remain uncertain given differences in pharmacokinetics and concerns for over-anticoagulation. Methods: This was a single-center, retrospective, pre-post study involving older adults aged\u2009\u2265\u200965\u00a0years and patients weighing\u2009\u2265\u2009100\u00a0kg with suspected or confirmed VTE to determine if the use of adjusted body weight (AdjBW)-based UFH regimens improves time to therapeutic anti-Xa levels compared to total body weight (TBW)-based regimens Patients received weight-based UFH infusions, dosed according to either TBW or AdjBW, to target a therapeutic anti-Xa level. Each cohort consisted of 40 patients, stratified by whether they met age or weight criteria to ensure equal representation of elderly and higher body weight patients between cohorts. The median time to therapeutic anti-Xa levels was shorter in the AdjBW group compared to the TBW group (13.6\u00a0h versus 20.9\u00a0h; point estimate 5.3\u00a0h (95% CI 0.2 to 9.9)). This finding was driven by those aged\u2009\u2265\u200965\u00a0years and those who received a bolus dose at the start of the infusion. Among older adults and higher weight adults with suspected or confirmed VTE, the use of AdjBW to guide heparin infusion initiation was associated with shorter time to therapeutic anti-Xa levels. This finding driven by the older adult sample and the subgroup analyses did not find a statistically significant difference in time to therapeutic anti-Xa levels in higher body weight patients aged less than 65\u00a0years.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s11239-024-03060-4","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T19:44:12Z","timestamp":1733341452000},"page":"420-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of unfractionated heparin therapy for venous thromboembolism using adjusted body weight in elderly or higher weight patients"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3821-7743","authenticated-orcid":false,"given":"Arielle J.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-8394","authenticated-orcid":false,"given":"Terence","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4447-0778","authenticated-orcid":false,"given":"Benjamin","family":"Pullinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-3994","authenticated-orcid":false,"given":"Sungwook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-6405","authenticated-orcid":false,"given":"Justin J.","family":"Delic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-505X","authenticated-orcid":false,"given":"Lauren A.","family":"Igneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8152-5148","authenticated-orcid":false,"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"6","key":"3060_CR1","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Baumann Kreuziger L et al (2021) Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):2247\u20132259. https:\/\/doi.org\/10.1016\/j.chest.2021.07.056","journal-title":"Chest"},{"key":"3060_CR2","unstructured":"Product Information: Heparin sodium intravenous, subcutaneous injection, heparin sodium intravenous, subcutaneous injection. Pfizer Labs (per DailyMed), New York, NY, 2019."},{"issue":"2","key":"3060_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4037\/aacnacc2020132","volume":"31","author":"T Williams-Norwood","year":"2020","unstructured":"Williams-Norwood T, Caswell M, Milner B et al (2020) Design and implementation of an anti-factor Xa heparin monitoring protocol. AACN Adv Crit Care 31(2):129\u2013137. https:\/\/doi.org\/10.4037\/aacnacc2020132","journal-title":"AACN Adv Crit Care"},{"issue":"9","key":"3060_CR4","doi-asserted-by":"publisher","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","volume":"119","author":"RA Raschke","year":"1993","unstructured":"Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S (1993) The weight-based heparin dosing nomogram compared with a \u201cstandard care\u201d nomogram. A randomized controlled trial. Ann Intern Med 119(9):874\u2013881. https:\/\/doi.org\/10.7326\/0003-4819-119-9-199311010-00002","journal-title":"Ann Intern Med"},{"issue":"2","key":"3060_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s11096-020-01004-5","volume":"42","author":"C George","year":"2020","unstructured":"George C, Barras M, Coombes J, Winckel K (2020) Unfractionated heparin dosing in obese patients. Int J Clin Pharm 42(2):462\u2013473. https:\/\/doi.org\/10.1007\/s11096-020-01004-5","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"3060_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/s-0038-1648450","volume":"67","author":"SH Ibbotson","year":"1992","unstructured":"Ibbotson SH, Tate GM, Davies JA (1992) Thrombin activity by intrinsic activation of plasma in-vitro accelerates with increasing age of the donor. Thromb Haemost 67(3):377\u2013380. https:\/\/doi.org\/10.1055\/s-0038-1648450","journal-title":"Thromb Haemost"},{"issue":"2","key":"3060_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0021-9150(93)90256-T","volume":"103","author":"K Kario","year":"1993","unstructured":"Kario K, Matsuo T (1993) Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. Atherosclerosis 103(2):131\u2013138. https:\/\/doi.org\/10.1016\/0021-9150(93)90256-T","journal-title":"Atherosclerosis"},{"issue":"4","key":"3060_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/01.ATV.20.4.902","volume":"20","author":"K Kurachi","year":"2000","unstructured":"Kurachi K, Kurachi S (2000) Genetic mechanisms of age regulation of blood coagulation. Arterioscler Thromb Vasc Biol 20(4):902\u2013906. https:\/\/doi.org\/10.1161\/01.ATV.20.4.902","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"3060_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","volume":"17","author":"JR Weinstein","year":"2010","unstructured":"Weinstein JR, Anderson S (2010) The aging kidney: physiological changes. Adv Chronic Kidney Dis 17(4):302\u2013307. https:\/\/doi.org\/10.1053\/j.ackd.2010.05.002","journal-title":"Adv Chronic Kidney Dis"},{"key":"3060_CR10","doi-asserted-by":"publisher","first-page":"107602961983348","DOI":"10.1177\/1076029619833480","volume":"25","author":"JW Schurr","year":"2019","unstructured":"Schurr JW, Muske AM, Stevens CA, Culbreth SE, Sylvester KW, Connors JM (2019) Derivation and validation of age- and body mass index-adjusted weight-based unfractionated heparin dosing. Clin Appl Thromb 25:1076029619833480. https:\/\/doi.org\/10.1177\/1076029619833480","journal-title":"Clin Appl Thromb"},{"issue":"6","key":"3060_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.soard.2008.03.005","volume":"4","author":"JF Barletta","year":"2008","unstructured":"Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton K (2008) Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 4(6):748\u2013753. https:\/\/doi.org\/10.1016\/j.soard.2008.03.005","journal-title":"Surg Obes Relat Dis Off J Am Soc Bariatr Surg"},{"key":"3060_CR12","first-page":"93","volume-title":"Applied clinical pharmacokinetics","author":"LA Bauer","year":"2001","unstructured":"Bauer LA (2001) Applied clinical pharmacokinetics. McGraw Hill, New York, pp 93\u2013179"},{"issue":"7\u20138","key":"3060_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1345\/aph.1Q161","volume":"45","author":"DJ Guervil","year":"2011","unstructured":"Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS (2011) Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 45(7\u20138):861\u2013868. https:\/\/doi.org\/10.1345\/aph.1Q161","journal-title":"Ann Pharmacother"},{"issue":"19","key":"3060_CR14","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2146\/ajhp150388","volume":"73","author":"J Fan","year":"2016","unstructured":"Fan J, John B, Tesdal E (2016) Evaluation of heparin dosing based on adjusted body weight in obese patients. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 73(19):1512\u20131522. https:\/\/doi.org\/10.2146\/ajhp150388","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm"},{"issue":"4","key":"3060_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Scientific the SOCOAOT, Thrombosis SC of the ISO, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03060-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:50:50Z","timestamp":1745038250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03060-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3060"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03060-4","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"2 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. We consulted extensively with the IRBs of Cooper University Hospital and Saint Joseph\u2019s University who determined that our study did not need ethical approval. An IRB official waiver of ethical approval was granted from the IRBs of Cooper University Hospital and Saint Joseph\u2019s University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}